Patents by Inventor Yuanping Liao

Yuanping Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12234479
    Abstract: This disclosure belongs to the field of biomedical technology, and particularly refers to a bifunctional molecule and the application thereof. The structure of the bifunctional molecule includes a first functional domain and a second functional domain. These domains are capable of simultaneously binding to T cells, thereby producing the first and second signals required for T cell activation. The bifunctional molecule is a recombinant protein-peptide, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and stable preparation process and product. The bifunctional molecule is superior to the current techniques in expanding T cells in vitro with lower protein dosage and simpler use procedure. It can be directly supplemented as soluble form without optimizing the relative ratio of full-length antibodies.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: February 25, 2025
    Assignee: CYTOCARES (SHANGHAI) INC.
    Inventors: Shuai Chen, Huaxing Zhu, Yuanping Liao
  • Publication number: 20230242876
    Abstract: This disclosure belongs to the field of biomedical technology, and particularly refers to a bifunctional molecule and the application thereof. The structure of the bifunctional molecule includes a first functional domain and a second functional domain. These domains are capable of simultaneously binding to T cells, thereby producing the first and second signals required for T cell activation. The bifunctional molecule is a recombinant protein-peptide, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and stable preparation process and product. The bifunctional molecule is superior to the current techniques in expanding T cells in vitro with lower protein dosage and simpler use procedure. It can be directly supplemented as soluble form without optimizing the relative ratio of full-length antibodies.
    Type: Application
    Filed: August 9, 2017
    Publication date: August 3, 2023
    Applicant: SHANGHAI SINOBIO BIOTECH CO., LTD.
    Inventors: Shuai CHEN, Huaxing ZHU, Yuanping LIAO
  • Patent number: 11535666
    Abstract: This disclosure belongs to the field of biomedical technology, and particularly refers to a trifunctional molecule and the application thereof. The structure of the trifunctional molecule includes a first functional domain, a second functional domain and a third functional domain. These domains are capable of simultaneously binding to CD19, CD3, and T cell positive (negative) costimulatory factors, thereby producing the first and second signal required for T cell activation. The trifunctional molecule is a recombinant protein peptide chain, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and preparation process and product stability. The trifunctional molecule is superior to the anti-CD19/anti-CD3 BiTE bispecific antibody in killing CD19-positive target cells.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 27, 2022
    Assignee: CYTOCARES (SHANGHAI) INC.
    Inventors: Shuai Chen, Huaxing Zhu, Yuanping Liao
  • Publication number: 20200207851
    Abstract: This disclosure belongs to the field of biomedical technology, and particularly refers to a trifunctional molecule and the application thereof. The structure of the trifunctional molecule includes a first functional domain, a second functional domain and a third functional domain. These domains are capable of simultaneously binding to CD19, CD3, and T cell positive (negative) costimulatory factors, thereby producing the first and second signal required for T cell activation. The trifunctional molecule is a recombinant protein peptide chain, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and preparation process and product stability. The trifunctional molecule is superior to the anti-CD19/anti-CD3 BiTE bispecific antibody in killing CD19-positive target cells.
    Type: Application
    Filed: August 9, 2017
    Publication date: July 2, 2020
    Applicant: CYTOCARES (SHANGHAI) INC.
    Inventors: Shuai CHEN, Huaxing ZHU, Yuanping LIAO
  • Patent number: D841639
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: February 26, 2019
    Assignee: SHENZHEN ZHIHAOTUO TECHNOLOGY CO. LTD
    Inventor: Yuanping Liao